Read by QxMD icon Read


Cortés Melissa Paola, Amaya María Camila, Cañas Ana, Osorio Marlon, Sánchez Diego, Zuluaga Robin, Gómez Beatriz, Castro Cristina
Collagen is the most abundant fibrous protein in animal's body and is widely used for biomedical and pharmaceutical applications. The principal sources of this protein are bovine, porcine and fish skin and bones. In Colombia, bovine bones are waste from meat industry, this material have potential as an alternative source of collagen isolation. The aim of this study was to evaluate the composition and some properties of type I collagen (COL I) extracted of bovine bones of Zebu-Bos Primigenius Indicus and its use as textile finishing to modify two types of fabrics: first a taffeta weave and the second a single jersey knit, both 100% cotton...
February 2019: Heliyon
Seema Pursnani, Raj Khandwalla, Rigved Tadwalkar
No abstract text is available yet for this article.
2016: Reviews in Cardiovascular Medicine
Frank H Büttner
The fifth international World Pharmaceutical Congress was organised by the Cambridge Healthtech Institute and contained six concurrent conferences in parallel. This report focuses on the third annual conference: 'Cell-based assays for HTS'. The major topics of this meeting were technologies for setting up screening assays, cells as biological reagents for screening campaigns, three-dimensional cell culture and the use of stem cells for drug screening. Technology-based presentations focused on the latest developments for cell-based screening, such as the open microscopy environment, a cell culture array as a kind of 'cell culture on a chip', a cellular microarray for analysing the binding behaviour of cells and aptamer technology...
September 2006: Expert Opinion on Drug Discovery
Mitchell Ho, Ivor Royston, Alain Beck
The 2nd Annual Antibodies for Cancer Therapy symposium, organized again by Cambridge Healthtech Institute as part of the Protein Engineering Summit, was held in Boston, USA from April 30th to May 1st, 2012. Since the approval of the first cancer antibody therapeutic, rituximab, fifteen years ago, eleven have been approved for cancer therapy, although one, gemtuzumab ozogamicin, was withdrawn from the market. The first day of the symposium started with a historical review of early work for lymphomas and leukemias and the evolution from murine to human antibodies...
September 2012: MAbs
Woody Sherman, Noeris Salam, Dora Warshaviak
No abstract text is available yet for this article.
September 2011: Future Medicinal Chemistry
Jack M Gallup, Mark R Ackermann
The purpose of this manuscript is to describe a reliable approach to quantitative real-time polymerase chain reaction (qPCR) assay development and project management, which is currently embodied in the Excel 2003-based software program named "PREXCEL-Q" (P-Q) (formerly known as "FocusField2-6Gallup-qPCRSet-upTool-001," "FF2-6-001 qPCR set-up tool" or "Iowa State University Research Foundation [ISURF] project #03407"). Since its inception from 1997-2007, the program has been well-received and requested around the world and was recently unveiled by its inventor at the 2008 Cambridge Healthtech Institute's Fourth Annual qPCR Conference in San Diego, CA...
December 15, 2008: International Journal of Biomedical Science: IJBS
Clara Campas
The Third Annual Drug Repositioning Summit 2008 was held at the Hyatt Harborside Hotel in Boston, Massachusetts, October 6-7, and focused on new strategies for drug repositioning. The meeting, organized by The Cambridge Healthtech Institute, brought together a panel of speakers from the industry and the academia, who discussed and proposed new routes for success in drug repositioning based on their own experience in the field. This meeting report summarizes the most relevant presentations and issues discussed...
March 2009: Drug News & Perspectives
Francis L Martin
Cambridge Health Tech Institute's first conference on 'The Future of Cancer Diagnostics: Next Generation Molecular Technologies' covered the following areas: regulatory requirements regarding the validation of new cancer diagnostics; how such validation processes might be suitably implemented from laboratory to clinical pipeline to the bedside; translational strategies, such as proteomics or methylation patterns; and novel biomarkers in oncology. Overall in this golden age of cancer research, the aims and objectives of the meeting were to explore how the implementation of new diagnostic strategies could be facilitated...
November 2008: IDrugs: the Investigational Drugs Journal
Alicia Demirjian, Ofer Levy
Vaccines are among the greatest achievements of modern medicine, leading to the eradication of naturally occurring smallpox, the near elimination of polio and the control of diseases such as rotavirus and hepatitis A and B in industrialized countries. Conventional vaccines, however, protect against a limited number of infectious diseases and, in some cases, provide incomplete protection. Effective vaccines against common infections such as HIV, hepatitis C and malaria remain an unmet medical need. These gaps, together with the threat of resurgence of eradicated diseases, contribute to the growing need for the development of new vaccines and the improvement of existing ones...
November 2008: Expert Review of Vaccines
R A Greenwald
This two-day meeting, sponsored by the Cambridge Healthtech Institute, was attended by around 70 scientists, primarily from the pharmaceutical industry, with a small number from academia. Most of the industry representatives were from smaller companies engaged in drug development; virtually no multinational companies were represented. Four main topics were covered: target identification and pathophysiology; structural analysis and drug design; screening for proteinase inhibitors; and, clinical development. The target identification session was by far the strongest...
June 1998: IDrugs: the Investigational Drugs Journal
Brian T Luke
No abstract text is available yet for this article.
November 2007: Expert Review of Molecular Diagnostics
Ateret Haselkorn, Molly J Coye, Charles R Doarn
Health Technology Center (HealthTech), a nonprofit research and education organization that develops objective technology forecasts, hosted an expert panel discussion aimed at delineating the future of remote health services (RHS). RHS is defined as involving patient care interactions that are geographically disparate and enabled by telecommunications, information technology, and sensor technology. Key players involved are physicians and nonphysician clinicians, sick or healthy individuals, and their friends or family...
June 2007: Telemedicine Journal and E-health: the Official Journal of the American Telemedicine Association
Richard D Beger
No abstract text is available yet for this article.
March 2007: Expert Review of Molecular Diagnostics
Cristina M Rondinone
The third annual conference on discovery on target, organised by the Cambridge Healthtech Institute was held on 19 - 20 October 2005, in Boston. More than 300 delegates from both academic and industrial institutes attended the meeting. The presentations provided insights into understanding the RNA interference technology as a useful tool to identify and validate new targets for therapeutic intervention. Discussions focused in the design of siRNA for effective gene silencing, RNAi screens to identify new targets, RNAi delivery and the in vivo validation of targets using this technology...
April 2006: Expert Opinion on Therapeutic Targets
H Kubinyi
This conference on recent developments in the discovery of novel therapeutic candidates was organized by Amy Dasch (Cambridge Healthtech Institute, Newton Upper Falls, MA, USA; The conference provided an overview of all relevant aspects of the rapidly changing paradigms in drug research. Gene technology creates a vast number of new biological targets. The progress in combinatorial chemistry and high-throughput screening (HTS) is accompanied by the development of virtual libraries, large screening programs, and the generation of enormous sets of data...
December 1998: IDrugs: the Investigational Drugs Journal
Vasker Bhattacherjee, Robert Greene, M Michele Pisano
No abstract text is available yet for this article.
July 2005: Expert Review of Molecular Diagnostics
Brian R Wong
The Cambridge Healthtech Institute Signal Transduction Conference covered three major topics over 2 days: the discovery of new signalling targets, improved technology to dissect out signal transduction pathways and the effects of small molecules on those pathways, and progress in the discovery and development of signalling modulators. There was a particular emphasis placed on the biology of protein kinases and industry efforts to develop efficacious and safe inhibitors for this target class. Of note, kinase inhibitors for therapeutic indications other than oncology, including those directed against inflammation, allergy and metabolic disorders, have reached or have nearly completed clinical testing...
February 2005: Expert Opinion on Investigational Drugs
(no author information available yet)
No abstract text is available yet for this article.
October 2004: Hospitals & Health Networks
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"